SCHEMBL6290148

SCHEMBL6290148

O=C1c2ccccc2C(=O)C1CCO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
S100A4 P26447 3/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
TDO2 P48775 1/20 0.42
LMNA P02545 2/20 0.41
TP53 P04637 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
MAPK1 P28482 2/20 0.41
HTR2B P41595 1/20 0.41
KDM4E B2RXH2 3/20 0.41
HBB P68871 2/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
SLC25A5 P05141 2/20 0.40
PIM1 P11309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10287951 0.81 MEN1 (0.48) MEN1KMT2AS100A4POLBMAPT
SCHEMBL23819694 0.78 SLC25A5 (0.39) MEN1KMT2AS100A4POLBMAPT
SCHEMBL10819272 0.77 MEN1 (0.44) MEN1KMT2AS100A4POLBMAPT
SCHEMBL30413587 0.74 TDO2 (0.61) KMT2APOLBTDO2LMNATP53
SCHEMBL2231461 0.74 TDO2 (0.61) KMT2APOLBTDO2LMNATP53
SCHEMBL22845855 0.74 GSK3B (0.42) MEN1KMT2AS100A4POLBMAPT
SCHEMBL1325541 0.74 RAB9A (0.44) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL28492311 0.72 SLC25A5 (0.49) MEN1KMT2AS100A4POLBMAPT
SCHEMBL86112 0.71 KMT2A (0.48) MEN1KMT2AS100A4POLBMAPT
SCHEMBL8365427 0.71 ALDH1A1 (0.58) MEN1KMT2AS100A4POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3536700-A1 PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES Ambrx, Inc. (US) 2019-09-11 EP disclosed
US-6867200-B1 (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-03-15 US disclosed
US-20030232789-A1 Salicylamides as serine protease and factor xa inhibitors ALLEN DARIN ARTHUR (US) 2003-12-18 US disclosed
US-20030225036-A1 Non-amidine containing protease inhibitors AXYS PHARMACEUTICALS, INC. 2003-12-04 US disclosed
EP-1242366-A1 SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-09-25 EP disclosed
US-20020052343-A1 Salicylamides as serine protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-05-02 US disclosed
WO-2001044172-A1 SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232789-A1 Salicylamides as serine protease and factor xa inhibitors TFPI, HABP2, PLAT MEN1 2391/4885KMT2A 1317/4885S100A4 1919/4885
US-20030225036-A1 Non-amidine containing protease inhibitors TFPI, SERPINE1, HABP2 MEN1 684/4885KMT2A 2549/4885S100A4 2761/4885
US-20020052343-A1 Salicylamides as serine protease inhibitors TFPI, SERPINE1, HABP2 MEN1 2151/4885KMT2A 1207/4885S100A4 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.